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Abstract
Background—Lymphangioleiomyomatosis (LAM), a multisystem disease occurring primarily in
women, is characterized by cystic lung destruction, and kidney and lymphatic tumors, caused by the
proliferation of abnormal-appearing cells (ie, LAM cells) with a smooth muscle cell phenotype that
express melanoma antigens and are capable of metastasizing. Estrogen receptors are present in LAM
cells, and this finding, along with reports of disease progression during pregnancy or following
exogenous estrogen administration, suggest the involvement of estrogens in the pathogenesis of
LAM. Consequently, antiestrogen therapies have been employed in treatment. The goal of this
prospective study was to evaluate the efficacy of triptorelin, a gonadotrophin-releasing hormone
analogue, in 11 premenopausal women with LAM.
Methods—Patients were evaluated at baseline and every 3 to 6 months thereafter, for a total of 36
months. Hormonal assays, pulmonary function tests, 6-min walk tests, high-resolution CT scans of
the chest, and bone mineral density studies were performed.
Results—Gonadal suppression was achieved in all patients. Overall, a significant decline in lung
function was observed; two patients underwent lung transplantation 1 year after study enrollment,
and another patient was lost to follow-up. Treatment with triptorelin was associated with a decline
in bone mineral density.
Conclusions—Triptorelin appears not to prevent a decline in lung function in patients with LAM.
Its use, however, may be associated with the loss of bone mineral density.
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Lymphangioleiomyomatosis (LAM), a multisystem disease primarily affecting women, is
characterized by the proliferation of abnormal-appearing cells (ie, LAM cells) that have a
smooth muscle cell phenotype expressing melanoma antigens and are capable of metastasizing,
leading to cystic destruction of the lungs, infiltration of the axial lymphatics (eg,
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lymphangioleiomyomas), and abdominal tumors (eg, angiomyolipomas).1–3 LAM occurs
sporadically or in association with tuberous sclerosis complex (TSC), an autosomal-dominant
syndrome that is characterized by mental retardation, seizures, hamartomatous growths,4 and
mutations in the tumor suppressor genes TSC1 and TSC2. These genes have been implicated
in the pathogenesis of sporadic LAM, as mutations and the loss of heterozygosity in the
TSC2 gene have been detected in LAM cells of patients without evidence of TSC.5 The
TSC1 gene encodes hamartin, and the TSC2 gene encodes tuberin, two proteins with roles in
cell growth, proliferation, and cytoskeletal organization.6
Patients with LAM may present with progressive breathlessness, pneumothorax, chylothorax,
asthmalike symptoms, or hemorrhage within angiomyolipomas.1–3 CT scans show numerous
thin-walled cysts throughout the lungs, abdominal angiomyolipomas, and
lymphangioleiomyomas.7 Pulmonary function test results may show a reduction in flow rates
and diffusing capacity of the lung for carbon monoxide (DLCO).2 Exercise testing may reveal
gas-exchange abnormalities, ventilatory limitation, and hypoxemia, which may occur with
near-normal lung function.8
The preferential occurrence of LAM in women during their reproductive years,1,2 the presence
of progesterone and estrogen receptors in LAM cells,9 and reports of deterioration of lung
disease during pregnancy10,11 or following the administration of estrogens,12,13 are consistent
with hormonal involvement in the pathogenesis of the disease. Treatments for LAM have
consisted mostly of oophorectomy and hormonal manipulations with progesterone or other
agents.14–21 In a retrospective analysis22 of lung function decline in 275 LAM patients,
however, no evidence was found of a beneficial effect of progesterone treatment.
The efficacy of gonadotrophin-releasing hormone (Gn-RH) agonists and analogues in the
treatment of LAM has also been the subject of several reports.23–25 Gn-RH analogues, such
as goserelin and triptorelin, are long-acting synthetic compounds that have high affinity for
neurohormonal receptors and a longer half-life than Gn-RH agonists.26 The long-term and
continuous administration of Gn-RH analogues causes a sustained decrease in luteinizing
hormone (LH) and follicle-stimulating hormone (FSH) secretion and a depression of gonadal
function.26 Prior experience with the treatment of LAM with Gn-RH analogues, consisting of
case reports,23,25 have yielded conflicting results. However, Medeiros et al,27 in a retrospective
analysis of lung function decline in patients with LAM, found that patients treated with
goserelin had no decline in lung function, whereas those patients treated with progesterone
continued to experience a decline. The goal of our study was to evaluate, prospectively, the
effect of treatment with triptorelin in premenopausal patients with LAM.
Materials and Methods
Study Population
This study evaluated the response to treatment with triptorelin, a synthetic analogue of Gn-RH
(11.25 mg IM every 3 months) in 11 premenopausal LAM patients. Informed consent was
obtained from all patients, and the protocol was approved by the San Giuseppe Hospital
Institutional Review Board.
Study Design
Patients were evaluated at baseline, and at 3, 6, 12, 18, 24, and 36 months after initiating
therapy. Routine blood testing and hormonal assays (ie, for FSH, LH, 17 β-estradiol, and total
testosterone) were performed every 6 months. Pulmonary function tests, arterial blood gas
measurements, 6-min walk tests (6MWT), and high-resolution CT (HRCT) scans were
performed once a year. Bone densitometry of the lumbar spine and femoral neck was measured
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at baseline and at 18 and 36 months after study enrollment. The primary end point of the study
was the decline in FEV1. Secondary end points were the 6MWT distance and changes in HRCT
lung scan findings.
Pulmonary Function Tests
Lung volumes, flow rates, and single-breath DLCO were measured (  229; SensorMedics;
Yorba Linda, CA), according to American Thoracic Society recommendations.28,29 Four of
the 11 patients had a history of a positive response to bronchodilators. All spirometric data
reported here are from prebronchodilator studies.
Arterial Blood Gases
Arterial blood samples were drawn from the radial artery of resting patients breathing room
air. Blood specimens were placed on ice, and tests were run immediately.
6MWT and Arterial Pulse Oximetry
6MWTs were performed using the protocol of Sciurba and Slivka.30 Patients were instructed
to walk as fast as possible for 6 min, while being encouraged using set phrases every 30 s.31
Two patients were exercised while receiving supplemental oxygen. For all patients, the test
was stopped if oxygen saturation dropped below 86%.32
Radiographic Assessment
HRCT scans of the chest were obtained (Tomoscan AV scanner; Philips; Amsterdam, the
Netherlands) at 10-mm intervals using 10-mm collimation during breath-holding at the end of
inspiration.33 A quantitative HRCT scan analysis was performed using the “density mask”
software on images from three lung zones (ie, aortic arch, left lower lobe bronchus origin, and
2 cm above the diaphragmatic muscle level) at end expiration, as previously reported.33 This
procedure identified areas of airtrapping. The percentage of airtrapping at the three standard
lung zones was calculated, and values were averaged; a final value was provided that reflected
the amount of airtrapping in both lungs.33
Bone Densitometry
The bone mineral density of the lumbar spine (anterior and lateral) and proximal femur was
assessed by dual-energy radiograph absorptiometry (QDR-4500; Hologic; Bedford, MA).34
The z scores were derived from age-matched reference values.34
Statistical Analysis
The yearly rate of decline in lung function was calculated from a linear regression using
FEV1 and DLCO as the response variables and the time of each test as the independent variable,
considering the first test as time zero.22 The Student t test was employed to compare data sets.
Analysis of variance (ANOVA) for repeated measurements was employed to evaluate changes
in physiologic and quantitative HRCT scan data. All reported p values are two-sided. All data
are shown as the mean ± SD.
Results
Characteristics of the Patients
Of the 11 patients (mean age, 37 ± 7 years; age range, 24 to 49 years), 9 had a histologically
proven diagnosis of LAM, and 2 patients exhibited clinical and radiographic features consistent
with LAM. Radiographic features consisted of the presence of thin-walled cysts scattered
throughout the lungs combined with abdominal angiomyolipomas and/or
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lymphangioleiomyomas.2 Three patients were ex-smokers; the remaining patients were
nonsmokers. One patient had LAM/TSC. Four patients had renal angiomyolipomas. Sequential
preenrollment pulmonary function data were available in three patients.
Therapy was initiated in all 11 patients; one patient failed to complete the study because of
drug-related adverse events. During the study, two patients underwent lung transplantation.
These patients continued to receive the study drug for only 1 year. For these two patients, the
data included in the analysis refer to pretransplant studies. Pneumothorax did not develop in
any patient while under treatment; two patients had subsequent episodes of pneumothorax.
Evidence for Gonadal Suppression: Adverse Effects
Treatment with triptorelin induced hypogonadotrophic hypogonadism (Table 1). Five patients
reported the following adverse events: four patients had flushing; two patients had arthralgias
and paresthesias; and two patients complained of fatigue and dizziness. Anxiety and depressive
symptoms developed in one patient. All patients, except those who underwent lung
transplantation and remained enrolled in the study for only 1 year, completed 3 years of
treatment.
Pulmonary Function, Arterial Blood Gas Measurements, and 6MWT Results
Table 2 shows initial pulmonary function test results, Pao2 measurements, and 6MWT findings
for every year until the completion of the study. ANOVA showed that the Pao2 at the third
year of the study was significantly lower than that at baseline (p < 0.01) and at the first year
of the study (p < 0.05). ANOVA showed no significant changes in lung function and 6MWT
results. This could be due to the fact that the number of patients remaining in the study decreased
after the first year and also because there is a large variance in lung function parameters among
the study subjects. However, at the end of the study, all but one patient had experienced declines
in FEV1 (Fig 1). Moreover, all nine patients who were able to perform the DLCO test had a
decline in function (Fig 2). Table 3 shows that, when compared to two previous retrospective
studies,21,22 the mean yearly declines in FEV1 (156 ± 184 mL; 4.9 ± 5.9% predicted) and
DLCO (1.3 ± 0.4 mL/min/mm Hg; 4.9 ± 5.0% predicted) were greater. One of the 10 patients
showed improvement in FEV1 and 6MWT distance during the 3 years of the study; in this
patient, FEV1 increased by 360 mL, and the 6MWT distance increased by 100 m. However,
this patient experienced a large yearly decline in DLCO (1.9 mL/min/mm Hg; 5.9% predicted).
Pre-study enrollment pulmonary function data were available only in three patients. The rate
of decline of FEV1 was unchanged in one patient; in the other two patients, the rate of FEV1
decline increased after initiating therapy with triptorelin. In one patient, the yearly rate of
change in FEV1 went from −60 to −137 mL/year, and in the second patient went from +10 to
−161 mL/year.
Quantitative HRCT Scans
Table 4 shows the mean percentage of airtrapping for the three standard lung zones at baseline
and at subsequent visits. An increase in values indicates the presence of a greater degree of
airtrapping, which presumably corresponds to an increase in the number and/or size of the lung
cysts. The percentage of airtrapping tended to increase in all but three patients (Table 4). For
the whole group, however, the change in the percentage of airtrapping was not statistically
significant.
Bone Mineral Density
Initial bone mineral density was normal in all patients. The mean lumbar spine and femoral
neck z scores were 1.328 ± 0.144 and 1.276 ± 0.248, respectively. At 36 months, the mean
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lumbar spine and femoral neck z scores had declined to 0.421 ± 1.268 (p = 0.04) and 0.524 ±
0.744 (p = 0.016), respectively. The yearly rate of decline in z scores, expressed as a percentage
of the initial values, was 22 ± 26% and 24 ± 26%, respectively. At the conclusion of the study,
two patients showed evidence of lumbar spine osteopenia.
Discussion
The goal of this study was to evaluate the effect of treatment with triptorelin, a Gn-RH analogue,
on lung function in patients with LAM. Although triptorelin was effective in suppressing
ovarian function, all but 1 of the 10 patients who completed the study experienced a decline
in FEV1; a reduction in DLCO was observed in all patients. In two cases, an accelerated loss of
lung function resulted in lung transplantation. Only one patient showed improvement in
FEV1 and 6MWT distance, despite deterioration in DLCO. The mean yearly rates of decline in
FEV1 and DLCO are higher than those observed by Johnson and Tattersfield21 and Taveira-
DaSilva et al.22 However, the rates of lung function decline in LAM patients are highly
variable; consequently, when relatively low numbers of patients are studied, the SD of the
average declines in FEV1 or DLCO are large. As shown in Table 3 in the study by Johnson and
Tattersfield,21 the mean rate of change in FEV1 was 108 ± 101 mL/year. In our retrospective
study of 275 patients, we found a mean rate of FEV1 decline of 75 ± 17 mL/year. It should be
noted that the 10 patients who are the subject of the current report had lower initial lung function
than the subjects of our retrospective study.22 This may explain why their decline in FEV was
higher.22 1 Indeed, the decline in FEV1 was lower in 5 of the 10 patients who had milder disease
than in the remaining patients (93 ± 54 vs 220 ± 102 mL/year, respectively). Because of the
small numbers of patients, the difference was not statistically significant. Interestingly, the
yearly rates of DLCO decline were similar for the same two subgroups of patients (1.24 ± 0.23
vs 1.33 ± 0.99 mL/min/mm Hg, respectively). Although it is possible that the milder disease
subgroup had a more benign disease course, their rate of FEV1 decline is comparable to that
reported by Johnson and Tattersfield.21 Consequently, we believe that our cohort as a whole
is representative of a LAM population, and treatment with a Gn-RH analogue failed to affect
disease progression. Based on the current study, we cannot say that triptorelin is actually
harmful.
Adverse effects of triptorelin such as flushing, arthralgia, paresthesias, fatigue, dizziness,
anxiety and depressive symptoms were observed, but only 1 of the 11 initial patients failed to
complete the study because of adverse events. In addition, a decline in bone mineral density
was observed after the administration of triptorelin. In a prior study,34 LAM patients had a
high frequency of abnormal bone density, which did not appear to be related to progesterone
therapy.
Antiestrogen therapies have been used in the treatment of LAM, but controlled trials23–25 have
not been performed. Prior experience with Gn-RH analogues, consisting of case reports or
retrospective studies comprising few patients, is conflicting. Our prospective study shows that
treatment with a Gn-RH analogue did not affect disease progression. Our observations
however, are based only on a group 10 patients, which may have excluded patients who are
more likely to respond to treatment; the study was not randomized, and disease severity varied
widely among patients.
Nobody expects hormonal therapy to cause the regression of cystic lung lesions. However,
such therapy, if effective, may arrest LAM cell growth, and decrease the size of
angiomyolipomas, lymphangioleiomyomas, and chylous effusions. It is accepted that
estrogens in some way facilitate the occurrence of LAM, making it almost exclusively a disease
of women. In addition, there is evidence that endogenous or exogenous estrogens (eg, from
pregnancy or estrogen-containing contraceptives) worsen LAM,10–13 but the reverse may not
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be true. That is, oophorectomy, antiestrogen therapy, or gonadotrophin analogues may not
improve disease progression in patients with LAM.
Our extensive retrospective study,22 including patients of all ages and grades of disease
severity, showed that those patients with more severe disease were more likely to be treated
with progesterone and those treated orally faired worse than groups given IM-administered
progesterone or no progesterone. The current study shows that the suppression of ovarian
function does not affect disease progression. This is true even in the subgroup of patients with
milder disease in whom we observed greater rates of decline in FEV1 and DLCO than those seen
in prior studies.21,22 In conclusion, our findings do not support a role for triptorelin, or similar
types of drugs, in the treatment of LAM. Of importance, this therapy appears to be associated
with adverse effects, especially bone mineral loss. We believe that oophorectomy or
antiestrogen therapy with progesterone or agents that suppress ovarian function does not
prevent or diminish lung disease progression in patients with LAM.
A possible beneficial effect of Gn-RH analogues in the therapy of selected LAM patients, such
as those with chylous effusions and lymphangioleiomyomas, cannot be completely excluded.
There are anecdotal reports of patients with chylous effusions whose conditions have
“improved” after treatment with progesterone and/or oophorectomy. Indeed, for lack of a better
treatment, antiestrogen therapy is occasionally prescribed for such patients. Our negative
findings, however, suggest that alternative therapeutic approaches rather than hormonal
therapies need to be sought for the treatment of LAM.
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ANOVA analysis of variance
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Figure 1.
Changes in FEV1 in 10 patients with LAM who were treated with triptorelin.
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Figure 2.
Changes in DLCO in nine patients with LAM who were treated with triptorelin.
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Table 1
Hormonal Levels in 10 Patients Treated With Triptorelin*
Hormones Initial(n = 10)
18 mo
(n = 8)
36 mo
(n = 8)
FSH,†mIU/mL 5.4 ± 3.5 4.2 ± 1.8 4.1 ± 2.4
LH,‡mIU/mL 1.8 ± 3.3 0.4 ± 0.2 0.21 ± 0.19
17 β-estradiol,§pg/mL 32.6 ± 23.1 19.5 ± 3.8 1.5 ± 2.2
*
Values are given as the mean ± SD.
†
Normal values, 2.8 to 11.3 mIU/mL.
‡
Normal values, 1.6 to 8.3 mIU/mL.
§
Normal values, 26 to 165 pg/mL.
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Table 2
Pulmonary Function and Exercise Data Before and During Triptorelin Therapy in 10 Patients With LAM*
Variables Initial(n = 10)
1 yr
(n = 10)
2 yr
(n = 8)
3 yr
(n = 8)
FVC
 L 2.9 ± 0.8 2.9 ± 1.0 3.2 ± 0.6 3.0 ± 0.8
 % predicted 75 ± 34 83 ± 28 93 ± 13 90 ± 18
FEV1
 L 1.9 ± 1.0 1.8 ± 1.1 2.0 ± 0.9 1.9 ± 0.9
 % predicted 64 ± 31 60 ± 34 68 ± 27 65 ± 26
FEV1/FVC 62 ± 23 57 ± 23 61 ± 23 60 ± 17
 ratio, %
TLC
 L 5.0 ± 0.4 4.6 ± 0.4 4.8 ± 0.3 4.8 ± 0.3
 % predicted 99 ± 13 95 ± 8 96 ± 10 96 ± 13
FRC
 L 2.9 ± 0.5 2.8 ± 0.5 3.0 ± 0.4 3.1 ± 0.7
 % predicted 107 ± 19 103 ± 19 113 ± 20 113 ± 27
RV
 L 1.8 ± 0.7 1.5 ± 0.6 1.6 ± 0.6 1.8 ± 0.8
 % predicted 121 ± 46 98 ± 36 100 ± 37 110 ± 53
RV/TLC 36 ± 13 33 ± 15 33 ± 12 36 ± 17
 ratio,%
DLCO
 mL/min/mmHg 15.5 ± 8.5 15.0 ± 8.0 15.8 ± 7.2 13.7 ± 6.6
 % predicted 58 ± 28 55 ± 27 59 ± 24 51 ± 21
Pao2, mm Hg 83 ± 8† 81 ± 9† 80 ± 10 75 ± 12
6MWT 458 ± 73 433 ± 179 459 ± 77 487 ± 95
 distance, m
*
Values are given as the mean ± SD. FRC = functional residual capacity; RV = residual volume; TLC = total lung capacity.
†
Significantly different from value at 3 years post-study enrollment by ANOVA (p < 0.05).
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Table 4
Average of Percent Lung Air-Trapping at Three Lung Zones Measured by Quantitative High-Resolution CT
Scans at Baseline and Subsequent Visits in 10 Patients With LAM*
Patient No. Initial 1 yr 2 yr 3 yr
1† 38 ± 6 52 ± 5
2 47 ± 4 49 ± 3 47 ± 3 55 ± 4
3† 47 ± 11 57 ± 10
4 7 ± 2 9 ± 2 14 ± 4 11 ± 2
5 39 ± 4 55 ± 5 39 ± 4 30 ± 9
6 17 ± 3 11 ± 3 13 ± 2 34 ± 16
7 12 ± 2 10 ± 3 7 ± 1 16 ± 3
8 32 ± 9 39 ± 8 40 ± 11 38 ± 11
9 5 ± 1 4 ± 1 5 ± 1 4 ± 2
10 9 ± 2 5 ± 1 12 ± 2 10 ± 1
*
Values are given as the mean ± SD.
†
Patients underwent lung transplantation.
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